Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
Source: SeekingAlpha
2025-12-06 01:18:57 ET
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy December 3, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular Dystrophy Transcript
Capricor Therapeutics Inc.
NASDAQ: CAPR
CAPR Trading
-6.86% G/L:
$30.97 Last:
1,644,147 Volume:
$33 Open:
CAPR Latest News
CAPR Stock Data
$1,278,443,622
46,286,693
0.54%
28
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
